Lista de obras - Scott Caroen - Dominio Público Uruguay

A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome

artículo científico publicado en 2017

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

artículo científico publicado en 2016

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet.

artículo científico publicado en 2018

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis.

artículo científico publicado en 2018

A note on improved statistical approaches to account for pseudoprogression

artículo científico publicado en 2018

A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs)

artículo científico publicado en 2018

BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors

artículo científico publicado en 2022

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells.

artículo científico publicado en 2018

CMET-46. INITIAL CLINICAL AND ADVANCED IMAGING OUTCOMES FROM A MULTI-INSTITUTIONAL PHASE I DOSE-ESCALATION TRIAL OF RRX-001 PLUS WHOLE BRAIN RADIATION FOR PATIENTS WITH BRAIN METASTASES

COVID-19 and Cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making

scientific article published on 19 August 2020

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance

artículo científico publicado en 2015

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

artículo científico publicado en 2016

Cushing's Syndrome, Cortisol, and Cognitive Competency: A Case Report

artículo científico publicado en 2017

Dysphonia after Bevacizumab Rechallenge: A Case Report

artículo científico publicado en 2015

Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management

artículo científico

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

artículo científico publicado en 2015

Follow the ATP: tumor energy production: a perspective

artículo científico publicado en 2014

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

artículo científico publicado en 2016

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

scientific article published on 24 May 2016

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

artículo científico publicado en 2016

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

artículo científico publicado en 2016

REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer

artículo científico publicado en 2019

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor.

artículo científico publicado en 2017

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

artículo científico publicado en 2016

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report

artículo científico publicado en 2016

Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix

artículo científico publicado en 2020

Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma

scientific article published on 11 December 2020

Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report

artículo científico publicado en 2017

The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.

artículo científico publicado en 2015

The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury

artículo científico publicado en 2017

The war on cancer: a military perspective

artículo científico publicado en 2015

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial

artículo científico publicado en 2016

Lista de obras de Scott Caroen

A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet.

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis.

A note on improved statistical approaches to account for pseudoprogression

A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs)

BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells.

CMET-46. INITIAL CLINICAL AND ADVANCED IMAGING OUTCOMES FROM A MULTI-INSTITUTIONAL PHASE I DOSE-ESCALATION TRIAL OF RRX-001 PLUS WHOLE BRAIN RADIATION FOR PATIENTS WITH BRAIN METASTASES

COVID-19 and Cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

Cushing's Syndrome, Cortisol, and Cognitive Competency: A Case Report

Dysphonia after Bevacizumab Rechallenge: A Case Report

Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

Follow the ATP: tumor energy production: a perspective

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor.

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report

Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix

Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma

Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report

The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.

The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury

The war on cancer: a military perspective

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial